Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

By H. W. Kim, J. Canchola, C. Brandt, G. Pyles, R. Chanock, K. Jensen, R. Parrott. 1969

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Palomo
2. P. Collins
3. V. Mas
4. Gale Smith
5. R. Fearns
6. R. Raghunandan
7. Michelle Thom
8. M. Magro

Citations in the corpus

• Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 (2020, neutral): “This metric has been identified as a potentially important indicator of vaccine safety, as high levels of binding yet non-neutralizing or weakly neutralizing Abs may contribute to vaccine-associated enhancement of respiratory disease (Graham, 2020; Kim et al., 1969; Polack et al., 2002).”
• Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats (2012, background): “Enhanced respiratory disease following natural infection was observed in children who received the FI-RSV vaccine in the 1960s [1,26,27] has been a major concern in the development of new RSV vaccines.”
• Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes (2011, background): “A series of RSV vaccine trials in the 1960s that evaluated an alum-precipitated formalin-inactivated whole virus did not prevent infection and caused enhanced disease severity upon natural RSV infection (11, 20, 22, 23), in part due to poor elicitation of fusion-inhibiting and neutralizing antibodie”
• Respiratory Syncytial Virus: Virology, Reverse Genetics, and Pathogenesis of Disease (2013, background): “Of 31 infants immunized with FI-RSV, 25 required hospitalization following natural infection and two died (Kim et al. 1969).”
• A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease (2002, methodology): “ERD was characterized by bronchoconstriction and pneumonia (2), both signs that may be associated with anaphylotoxin activity (27–30).”
• Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses (2016, background): “formalin-inactivated (FI) virus vaccine in the 1960s (2).”
• SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness (2020, unknown): “Vaccine-associated enhanced respiratory disease (VAERD) has been associated with T helper 2 cell (T H 2)-biased immune responses in children immunized with whole-inactivated-virus vaccines against RSV and measles virus 26,27 .”
• Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention (2012, methodology): “A trial conducted with formalin-inactivated hRSV in the 1960s did not confer protection and was associated with enhanced disease in infants upon natural infection with the virus (3).”